title: Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy.
abstract: Histone deacetylase (HDAC) enzymes play a critical role in the epigenetic regulation of cellular functions and signaling pathways in many cancers. HDAC inhibitors (HDACi) have been validated for single use or in combination with other drugs in oncologic therapeutics. An even more novel combination therapy with HDACi is to use them with an oncolytic virus. HDACi may lead to an amplification of tumor-specific lytic effects by facilitating increased cycles of viral replication, but there may also be direct anticancer effects of the drug by itself. Here, we review the molecular mechanisms of anti-cancer effects of the combination of oncolytic viruses with HDACi.
authors: Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
authors: Hiroshi
authors: H
authors: Nakashima
authors: Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
authors: Tran
authors: T
authors: Nguyen
authors: Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
authors: Ennio Antonio
authors: EA
authors: Chiocca
keywords: HDAC inhibitor; HSV-1; cancer; epigenetics; glioma; oncolytic virus